Antibody composition and passive immunization against pregnancy-induced hypertension

A pharmaceutical composition of digoxin antibody for administration to a mammal who is not intoxicated by an exogenous cardenolide or bufadienolide, comprising a high dose digoxin antibody as an active ingredient, wherein said high dose digoxin antibody is therapeutically effective for treating a symptom or condition associated with the presence of an endogenous inhibitor of Na+/K+ ATPase.

A pharmaceutical composition comprising a high dose digoxin antibody as an active ingredient in a single application dose, wherein said high dose digoxin antibody is therapeutically effective for treating gestational hypertension, preeclampsia, eclampsia, or intrauterine growth restriction.

A composition of digoxin antibody as a single application dose, comprising as an active ingredient an amount of digoxin antibody having greater than 0.006 mg digoxin binding capacity per kilogram of weight of a mammal to whom the composition is to be administered, wherein said mammal is not intoxicated by an exogenous cardenolide or bufadienolide, and wherein said high dose digoxin antibody is therapeutically effective for treating gestational hypertension, preeclampsia, eclampsia, or intrauterine growth restriction.

A method of treating gestational hypertension, preeclampsia, eclampsia or intrauterine growth restriction, comprising the steps of:

• (a) selecting a composition from Table II.A, Table II.B or Table III;
• and
• (b) administering the composition to a mammal in need thereof.

A method for determining a composition of digoxin antibody to be administered to a mammal at risk for developing or demonstrating one or more causes or symptoms or complications of gestational hypertension, preeclampsia, eclampsia or intrauterine growth restriction, comprising:

• (a) providing the weight of a mammal;
• (b) selecting a serum “digoxin” concentration between 0.1 ng/mL and 2.0 ng/mL;
• (c) selecting a digoxin antibody composition from among the range of compositions described in Table II.A, Table II.B or Table III, wherein said composition is selected based upon the values obtained in steps (a) and (b).

A method for treating gestational hypertension, preeclampsia, eclampsia or intrauterine growth restriction in mammal, comprising the step of administering at least one composition of digoxin antibody to a subject mammal, wherein said composition has a digoxin binding capacity between greater than 0.006 and approximately 10 milligrams per kilogram of the weight of said mammal.

A method for treating gestational hypertension, preeclampsia, eclampsia or intrauterine growth restriction in a mammal, comprising the step of administering to a mammal a composition capable of interfering with an effect of an endogenous Na+/K+ ATPase inhibitor on said mammal, wherein said administration is for a time and in an amount therapeutically effective to treat gestational hypertension, preeclampsia, eclampsia or intrauterine growth restriction.

A pharmaceutical composition comprising a compound capable of binding digoxin, digitoxin, digitoxigenin, digoxigenin, or gitoxingenin, wherein said composition has the ability to bind greater than 0.006 mg of digoxin digitoxin, digitoxigenin, digoxigenin, or gitoxingenin per kilogram body weight of a mammal to whom the composition will be administered, and wherein said composition is therapeutically effective for treating a cause, a symptom or a complication of a condition associated with an endogenous inhibitor of Na+/K+ ATPase.